Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2014, Article ID 263720, 5 pages
http://dx.doi.org/10.1155/2014/263720
Clinical Study

Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients

1Faculty of Medicine, Hospital de Clínicas, Federal University of Paraná, Rua Alvaro Alvin 224, Casa 18, Seminário, 80740260 Curitiba, PR, Brazil
2Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, PR, Brazil

Received 4 November 2013; Accepted 3 January 2014; Published 12 February 2014

Academic Editor: Luis R. Espinoza

Copyright © 2014 Valderilio Feijó Azevedo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. U. R. Smith, C. Diaz-Torne, F. Perez-Ruiz, and L. M. March, “Epidemiology of gout: an update,” Best Practice & Research, vol. 24, no. 6, pp. 811–827, 2010. View at Google Scholar
  2. E. Roddy and M. Doherty, “Epidemiology of gout,” Arthritis Research and Therapy, vol. 12, no. 6, article 223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. H. Pillinger, D. S. Goldfarb, and R. T. Keenan, “Gout and its comorbidities,” Bulletin of the NYU Hospital for Joint Diseases, vol. 68, no. 3, pp. 199–203, 2010. View at Google Scholar · View at Scopus
  4. A. K. Tausche, T. L. Jansen, H. E. Schröder, S. R. Bornstein, M. Aringer, and U. Müller-Ladner, “Gout-current diagnosis and treatment,” Deutsches Ärzteblatt International, vol. 106, no. 34-35, pp. 549–555, 2009. View at Google Scholar
  5. E. Roddy, W. Zhang, and M. Doherty, “Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations,” Annals of the Rheumatic Diseases, vol. 66, no. 10, pp. 1311–1315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Rothenbacher, P. Primatesta, A. Ferreira, L. Cea-Soriano, and L. A. G. Rodríguez, “Frequency and risk factors of gout flares in a large population-based cohort of incident gout,” Rheumatology, vol. 50, no. 5, Article ID keq363, pp. 973–981, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. So, “Developments in the scientific and clinical understanding of gout,” Arthritis Research and Therapy, vol. 10, no. 5, article 221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Terkeltaub, “Novel therapies for treatment of gout and hyperuricemia,” Arthritis Research & Therapy, vol. 11, article 236, 2009. View at Publisher · View at Google Scholar
  9. J. A. Singh, S. G. Reddy, and J. Kundukulam, “Risk factors for gout and prevention: a systematic review of the literature,” Current Opinion in Rheumatology, vol. 23, no. 2, pp. 192–202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Kunishima, I. Inoue, T. Oikawa, H. Nakajima, T. Komoda, and S. Katayama, “Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors,” PPAR Research, vol. 2007, Article ID 36092, 5 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Dubchak and G. F. Falasca, “New and improved strategies for the treatment of gout,” International Journal of Nephrology and Renovascular Disease, vol. 3, pp. 145–166, 2010. View at Google Scholar · View at Scopus
  12. S. Kumar, J. Ng, and P. Gow, “Benzbromarone therapy in management of refractory gout,” New Zealand Medical Journal, vol. 118, no. 1217, Article ID U1528, 2005. View at Google Scholar · View at Scopus
  13. M. M. van der Klauw, P. M. Houtman, B. H. C. Stricker, and P. Spoelstra, “Hepatic injury caused by benzbromarone,” Journal of Hepatology, vol. 20, no. 3, pp. 376–379, 1994. View at Google Scholar · View at Scopus
  14. S. Sutaria, R. Katbamna, and M. Underwood, “Effectiveness of interventions for the treatment of acute and prevention of recurrent gout—a systematic review,” Rheumatology, vol. 45, no. 11, pp. 1422–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Perez-Ruiz, A. Alonso-Ruiz, M. Calabozo, A. Herrero-Beites, G. García-Erauskin, and E. Ruiz-Lucea, “Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout,” Annals of the Rheumatic Diseases, vol. 57, no. 9, pp. 545–549, 1998. View at Google Scholar · View at Scopus
  16. M. K. Reinders, E. N. van Roon, P. M. Houtman, J. R. B. J. Brouwers, and T. L. T. A. Jansen, “Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients,” Clinical Rheumatology, vol. 26, no. 9, pp. 1459–1465, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. K. Reinders, E. N. van Roon, T. L. T. A. Jansen et al., “Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol,” Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 51–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. K. Reinders, C. Haagsma, T. L. T. A. Jansen et al., “A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 892–897, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. K. Tausche, C. Wunderlich, and M. Aringer, “Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma,” Case Reports in Medicine, vol. 2011, Article ID 397646, 3 pages, 2011. View at Publisher · View at Google Scholar
  20. T. Yamamoto, Y. Moriwaki, S. Takahashi, M. Suda, and K. Higashino, “Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol,” Annals of the Rheumatic Diseases, vol. 50, no. 9, pp. 631–633, 1991. View at Google Scholar · View at Scopus
  21. F. Perez-Ruiz, M. Calabozo, J. I. Pijoan, A. M. Herrero-Beites, and A. Ruibal, “Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout,” Arthritis Care and Research, vol. 47, no. 4, pp. 356–360, 2002. View at Google Scholar · View at Scopus
  22. M.-H. H. Lee, G. G. Graham, K. M. Williams, and R. O. Day, “A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients?” Drug Safety, vol. 31, no. 8, pp. 643–665, 2008. View at Publisher · View at Google Scholar · View at Scopus